TTK Healthcare Research Report - 16th Dec 2015

Miscellaneous | Published on Dec 17th 2012


TTK Healthcare (TTKH), a part of the TTK group is present across businesses like pharmaceuticals, consumer products, medical devices and foods. The company has leading brands like Woodward’s Gripe Water with more than 50% market share and Eva which is a leader in women’s deodorant segment. TTKH’s continuous advertisement spend has resulted in suboptimal RoE, although the same is expected to reap benefits in the long term. With termination of the low margin condoms distribution business, the top-line is expected to be impacted by ~20%. The company’s increasing focus on branded foods - a high RoE business, and orthopaedic implants - a niche product in a nascent stage; provide long term growth opportunities. We initiate coverage on the stock, with a Buy recommendation and a target price of `643.

Download Full Report


CMP 551
Target Price 643
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Public & Others31.0
Grand Total100.0

Trade Securely


Portfolio Tracking & Trading Application View Demo